Miami ibogaine treatment: the local guide

Is ibogaine legal in Miami and Florida?

No. Ibogaine is a Schedule I controlled substance federally, and Florida has not created a state exemption or therapeutic access pathway. Any Miami-based operation offering ibogaine dosing on US soil is operating outside the law and almost certainly outside medical oversight.

That legal reality is why the credible Miami pathway is preparation and aftercare locally, with dosing performed at a licensed or lawfully operating facility abroad — most commonly in Mexico, Costa Rica, Portugal, or New Zealand. Direct flights from Miami International reach most Latin American programs in under four hours.

Miami psychedelic therapy: what is and isn't available

Searches for Miami psychedelic therapy turn up a fast-growing scene, but the legal menu is narrow. Ketamine is the only psychedelic-adjacent medicine lawfully administered in Miami today, through licensed ketamine clinics and telehealth prescribers. Psilocybin and MDMA remain unavailable outside clinical trials, and ibogaine has no lawful access pathway in Florida at all.

The meaningful local development is research, not retail. The University of Miami built one of the country's notable ibogaine programs in the 1990s and, in 2026, gifted its historic ibogaine investigational new drug file to the federal government — a signal that Miami institutions are pushing this molecule toward legitimate US trials rather than underground use. Miami patients following psychedelic therapy should expect trial-based access, not clinic-based access, for the foreseeable future.

Where Miami addiction clinics fit in the ibogaine pathway

Miami addiction clinics cannot administer ibogaine, but the good ones are central to doing it safely. Local addiction medicine physicians and detox programs handle the work that determines whether ibogaine is even an option: medically supervised detox, tapering from long-acting opioids like methadone to short-acting alternatives, medication reconciliation, and psychiatric stabilization.

When evaluating Miami addiction clinics as part of an ibogaine plan, look for board-certified addiction medicine or addiction psychiatry, experience with opioid taper protocols, and willingness to coordinate with an overseas treatment team. A clinic that has never heard of ibogaine is not a disqualifier; a clinic that promises to arrange dosing in Miami is.

What Miami patients can arrange locally

• Cardiology workup: 12-lead ECG, QTc measurement, echocardiogram where indicated
• Comprehensive metabolic panel, liver and renal function, magnesium and potassium
• Psychiatric assessment and medication reconciliation (SSRIs, methadone, QT-prolonging drugs)
• Opioid taper planning — most protocols require a switch from long-acting to short-acting opioids
• Medically supervised detox at a licensed Miami or South Florida facility
• Post-treatment integration therapy and relapse-prevention care in South Florida

How to vet an ibogaine program from Miami

• A physician on site for the full dosing window, not on call
• Continuous telemetry ECG throughout the session and overnight
• Written screening protocol, including automatic exclusion for QTc above threshold
• Emergency medications and defibrillation on site, with a hospital transfer agreement
• Named aftercare plan of at least 30 days, not a discharge on day three
• Transparent pricing with no cure claims and no pressure to book immediately

Cost and logistics from South Florida

Supervised programs typically run from roughly US$6,000 to US$12,000 for a week-long stay, excluding flights and pre-treatment cardiology. Direct flights from Miami reach most Latin American clinics in under four hours, which is one reason Miami became a hub for this care pathway.

Budget separately for pre-treatment testing in Miami, a companion where possible, and at least a month of structured aftercare. The aftercare line item is the one most often skipped and the one most correlated with sustained outcomes.

Third-party information about clinical records

Public information from ibogaine.nz describes a clinical record containing clinician-entered contraindication screening, interaction reviews, QTc and vital-sign values measured with separate equipment, an adverse-event register, and PHQ-9, GAD-7, craving, sleep and mood assessment records.

The published record structure includes follow-up entries at 1 week, 1 month, 3 months and 6 months. Numeric threshold prompts, including 460 ms and 500 ms QTc parameters, are clinician-configured and clinician-reviewed. This app does not replace clinical care. Ibogaine is available in New Zealand by prescription only.